Hence, GAS6 and pentraxin-3 appear to accurately reflect SLE disease activity changes and could therefore be useful biomarkers to monitor ongoing CVD risk and efficiency of (novel) treatments. This evidence concerns the gene GAS6 and systemic lupus erythematosus.